CVS Health Corp vs TJX Companies Inc — how do they compare? CVS Health Corp trades at $86.16 (market cap $112.29B), while TJX Companies Inc trades at $138.76 (market cap $152.62B). The key difference: TJX Companies Inc is the larger of the two by market cap, and CVS Health Corp pays the higher dividend (3.03%). Which is the better fit depends on your goals — on Pluang, investors hold CVS Health Corp for 83 Days and TJX Companies Inc for 97 Days on average.
| CVS | TJX | |
|---|---|---|
Market Cap | $112.29B | $152.62B |
Volume | 7,763,676 | 8,079,794 |
Sector | Health | Consumer Cyclical |
52-Week High | $110.60 | $168.41 |
52-Week Low | $70.08 | $122.84 |
Typical Hold Time | 83 Days | 97 Days |
Enterprise Value | $174.64B | $160.93B |
Dividend Yield | 3.03% | 1.38% |
Signals from Pluang's Aura AI — not financial advice
CVS Health trades at $87.80, down 0.17% on the day, with a bearish technical signal and neutral oscillators. The company reported strong earnings beats in recent quarters, with Q2 2026 EPS of $2.58 exceeding the $1.85 estimate. Revenue grew to $402.07B in 2025, though net income margin compressed to 1.18%. Recent news highlights Aetna's 2027 Medicare plan updates and a quarterly dividend declaration.
CVS presents a mixed outlook with solid revenue growth and analyst bullishness (85% buy ratings, $111.20 consensus target) offset by profitability pressures and a bearish technical trend. Key risks include reimbursement pressure and ongoing legal investigations, but the stock offers value with a low P/S of 0.27 and dividend yield support.
TJX trades at $138.75, down 0.04% on the day, with strong fundamental performance including 62.17% ROE and consistent earnings beats. The stock shows bullish technical momentum with support at $136 and resistance at $140. Revenue grew to $56.36B in 2025 with net income reaching $4.86B, while analyst consensus remains overwhelmingly positive with 85% buy ratings.
TJX presents a compelling investment case with projected 28% upside to the $174.15 consensus target, supported by expanding profit margins and robust cash flow generation. Key risks include competitive pressures in off-price retail and potential consumer spending volatility. The company's strong balance sheet and consistent dividend payments provide stability amid market fluctuations.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Following its acquisition of Aetna in late 2018, CVS Health now provides an even more integrated healthcare-services offering for its members. Legacy CVS combined both the largest pharmacy benefit manager, processing over 2 billion adjusted claims annually, and a sizable pharmacy operation, including nearly 10,000 retail pharmacy locations primarily in the U.S. Adding a managed-care organization with 24 million medical members gives the company a strong position in the insurance industry and should help CVS better control overall healthcare costs for its clients.
Read more on CVS →TJX is a leading off-price retailer of apparel, home fashions, and other merchandise. It sells a variety of branded goods, opportunistically buying inventory from a network of over 21,000 vendors worldwide. TJX targets undercutting conventional retailers' regular prices by 20%-60%, capitalizing on a flexible merchandising network, relatively low-frills stores, and a treasure-hunt shopping experience to drive margins and inventory turnover. TJX derived 79% of fiscal 2022 revenue from the United States, with 11% from Europe (mostly the United Kingdom and Germany), 9% from Canada, and the remainder from Australia. The company operated 4,689 stores at the end of fiscal 2022 under the T.J. Maxx, T.K. Maxx, Marshalls, HomeGoods, Winners, Homesense, Winners, and Sierra banners.
Read more on TJX →